Alexis Pinto - Oct 25, 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Legal Officer
Signature
/s/ Melissa B. Epperly, Attorney-in-Fact for Alexis Pinto
Stock symbol
ZNTL
Transactions as of
Oct 25, 2021
Transactions value $
-$1,300,002
Form type
4
Date filed
10/27/2021, 08:13 PM
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Options Exercise $1.03M +30K +459.7% $34.40 36.5K Oct 25, 2021 Direct F1, F2
transaction ZNTL Common Stock Sale -$137K -1.8K -4.93% $76.10 34.7K Oct 25, 2021 Direct F1, F3
transaction ZNTL Common Stock Sale -$626K -8.1K -23.32% $77.27 26.6K Oct 25, 2021 Direct F1, F4
transaction ZNTL Common Stock Sale -$1.55M -19.8K -74.37% $78.05 6.83K Oct 25, 2021 Direct F1, F5
transaction ZNTL Common Stock Sale -$23.7K -300 -4.39% $78.85 6.53K Oct 25, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Options Exercise $0 -30K -10.91% $0.00 245K Oct 25, 2021 Common Stock 30K $34.40 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2 Includes 276 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.57 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.59 to $77.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.59 to $78.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter.